BiomedicalPublications

Drug Target Insights

SAGE Publishing·Italy·ISSN 1177-3928

Open accessIn DOAJMedicine

Drug Target Insights is published by SAGE Publishing as an open access journal (ISSN 1177-3928). The list article processing charge is $1,617. Typical time to publication is 8 wks. Its OpenAlex h-index is 27. Primary field: Medicine. It is listed in the Directory of Open Access Journals. Figures on this page are sourced from OpenAlex and DOAJ and should be confirmed on the journal’s own site before submission.

Cost to publish

$1,617

Open-access article processing charge, list price.

Checked · Journal fee page

Time to publication

8 wks

Fast for a peer-reviewed journal — check what review depth that implies.

h-index

27

OpenAlex citation statistic. Not a Journal Impact Factor.

2-year mean citedness

3.6

Average citations to articles from the previous two years.

What it costs to publish here

Publishing an open-access article in Drug Target Insights is listed at $1,617. The publisher also lists 1,500 EUR. No waiver policy is recorded in our sources, which does not mean none exists. Ask.

The journal's own fee page →

What this journal has charged over time

List price for an open-access article in Drug Target Insights, as recorded by OpenAlex for each year. The fee has risen 10% since 2019, from $1,680 to $1,848.

$0$924$1.8k2019: $1,68020192020: $1,8482020

Publishers change list prices without notice and often apply discounts, institutional agreements or waivers. Treat this as the trend, and confirm the current figure with the journal.

Peer review and licensing

Review modelAnonymous peer review (policy)
LicenceCC BY-NC
Author keeps copyrightNo
Plagiarism screeningYes
Editorial boardPublished →
LanguagesEN

Verification checks

8 of 8 confirmed

These are facts we could verify in public records, not a verdict. A journal missing a check is not necessarily disreputable — many long-established subscription journals sit outside the open-access registries entirely. Use them as questions to ask, and confirm anything that matters directly with the journal before you submit.

  • Listed in the Directory of Open Access JournalsDOAJ applies a documented set of inclusion criteria.
  • Included in OpenAlex's curated core setOpenAlex flags well-established venues that appear across major indexes.
  • Peer review model publicly declaredAnonymous peer review
  • Publication charges stated up frontA journal that will not tell you the fee before submission is worth a second look.
  • Screens submissions for plagiarismReported to DOAJ by the journal.
  • Participates in a digital preservation schemeArchiving means the record survives if the publisher does not.
  • Assigns persistent identifiers (DOIs)Standard practice; its absence is unusual.
  • Still actively publishingMost recent indexed article: 2025.

Scope

The subjects Drug Target Insights publishes most, derived from the topics assigned to its indexed articles.

Antibiotic Resistance in BacteriaPharmacological Effects of Natural CompoundsGastrointestinal motility and disordersComputational Drug Discovery MethodsDiabetes Treatment and ManagementAntibiotic Use and ResistanceNanoparticle-Based Drug DeliveryDrug Solubulity and Delivery SystemsHIV/AIDS drug development and treatmentRNA Interference and Gene Delivery

Publication record

Indexed articles242
Total citations3,365
i10-index71
Most recent indexed article2025
Open access since2006
All ISSNs1177-3928

Counts reflect what OpenAlex has indexed and will differ from the publisher's own figures. We do not show a founding year: OpenAlex's first-publication dates are distorted by mis-dated records — it puts PLoS ONE in 1806 — and we would rather omit a number than print one we cannot stand behind.